Table 2.
Primary and Secondary Outcomes.
| Outcome | Overall N | Hypothermia Group |
Normothermia Group |
Risk Difference (95% CI) |
Relative Risk (95% CI) |
P value |
|---|---|---|---|---|---|---|
| Primary Outcome | ||||||
| Alive and VABS-II score ≥ 70 at one year | 65 | 12/41 (29%) | 4/24 (17%) | 12.6% (−7.8%, 33.0%) | 1.74 (0.61, 4.95) | 0.27* |
| Secondary Outcomes | ||||||
| Alive at one year | 69 | 21/43 (49%) | 11/26 (42%) | 6.5% (−17.6%, 30.7%) | 1.16 (0.68, 1.99) | 0.58* |
| One year change in VABS-II score from baseline |
68 | n=43 | n=25 | 0.46‡ | ||
| Death | 22 (51%) | 15 (60%) | ||||
| Lowest possible VABS-II score | 0 (0%) | 0 (0%) | ||||
| VABS-II score decreased > 30 points | 8 (19%) | 4 (16%) | ||||
| VABS-II score decreased 16–30 points | 3 (7%) | 1 (4%) | ||||
| VABS-II score decreased no more than 15 points or improved | 10 (23%) | 5 (20%) |
*
P value reflects the Cochran-Mantel-Haenszel test, adjusted for age stratum.
‡
P value reflects the Mann-Whitney test based on the continuous change in VABS score, stratified by age category. Deceased patients and those with the lowest possible VABS score are assigned ranks of −2000 and −1000, respectively (i.e., the worst possible scores).